Wondfo Solutions for Women’s Health Diagnostics | CLIA & FIA

Women's health testing covers a wide range of clinical needs, from reproductive hormone assessment and pregnancy-related testing to thyroid function evaluation, thyroid-related tumor marker testing, gynecological tumor marker monitoring, and TORCH screening. For hospitals and clinical laboratories, the challenge is not only assay coverage, but also workflow efficiency, reliable quantitative results, sample handling, and turnaround time.
As testing demand grows across gynecology, reproductive medicine, endocrinology, oncology-related follow-up, and laboratory departments, fully automated chemiluminescence immunoassay systems are becoming an important part of modern women's health diagnostic workflows.
Wondfo SmarLumi™ FC-2100 is a fully automated chemiluminescence immunoassay analyzer designed to support high-efficiency laboratory testing with broad assay coverage, flexible sample handling, and automated operation.

Why Women's Health Testing Requires Reliable Diagnostic Workflows

Women's health diagnostics often involves multiple testing needs across different stages of care. A patient may require reproductive hormone testing, pregnancy-related assessment, thyroid function testing, thyroid autoantibody testing, tumor marker monitoring, or TORCH-related testing depending on clinical context.
Thyroid testing deserves a clear place in women's health workflows. Thyroid dysfunction can be clinically relevant in reproductive health, pregnancy-related care, and endocrine assessment, while thyroid cancer is more frequently diagnosed in women than in men. For laboratories, this makes thyroid function and thyroid-related markers important additions to women's health testing menus rather than a separate topic outside the workflow.
For healthcare professionals, timely access to reliable results can support more informed clinical decisions and improve testing workflow management. In laboratory environments, this requires platforms that can manage diverse assay menus, support quantitative testing, and fit both routine and urgent testing needs.
A testing platform with broad menu coverage can help laboratories consolidate workflows across reproductive endocrinology, thyroid and endocrine testing, gynecological tumor markers, TORCH, and supporting biomarker testing.

Fully Automated CLIA in Women's Health Diagnostic Testing

Chemiluminescence immunoassay, or CLIA, is widely used in clinical laboratories for quantitative immunoassay testing. Compared with manual or semi-automated workflows, fully automated CLIA systems can help laboratories improve throughput, reduce repetitive handling, and support standardized testing processes.
For women's health testing, fully automated CLIA is especially useful when laboratories need to manage multiple reproductive hormone, thyroid function, thyroid autoantibody, tumor marker, and infectious disease-related assays on one platform. This makes CLIA suitable for hospitals, central laboratories, reproductive medicine centers, endocrinology departments, and clinical testing facilities with regular women's health testing demand.

SmarLumi™ FC-2100: Fully Automated CLIA Analyzer for Clinical Laboratories

Wondfo SmarLumi™ FC-2100 is built for efficient laboratory workflows. The system supports up to 200 tests per hour and delivers the first result in less than 12 minutes. With 60 sample positions, 25 reagent positions, and only a 0.64 m² footprint, FC-2100 is designed to balance testing capacity with compact laboratory placement.
The analyzer supports batch and STAT modes, 2-8°C on-board reagent refrigeration, bidirectional LIS compatibility, built-in touch screen operation, automatic dilution, and storage capacity of at least 60,000 results. These features can help laboratories handle routine testing, urgent samples, and multi-assay workflows more efficiently.
Key FC-2100 workflow advantages are summarized below:

Women's Health Assay Coverage on SmarLumi™ FC-2100

Instead of treating women's health as a single test area, laboratories often need a connected menu across reproductive hormones, thyroid function, thyroid autoimmunity, tumor markers, and TORCH-related testing. FC-2100 supports these needs through a broad CLIA assay portfolio.

This menu breadth allows the article to retain important SEO terms such as thyroid function testing, TSH test, FT3 test, FT4 test, thyroid cancer marker, AMH test, β-HCG test, CA125 test, fertility hormone testing, and reproductive hormone testing without turning the body copy into a long vertical list.
 

Why Thyroid Testing Should Be Included in Women's Health CLIA Workflows

A women's health testing article can feel incomplete if it only discusses reproductive hormones and gynecological tumor markers. Thyroid function testing is closely connected with endocrine health, reproductive health, and pregnancy-related assessment, so laboratories often need thyroid assays as part of a broader women's health menu.
Women are also more frequently affected by thyroid disorders, and thyroid cancer is diagnosed more often in women than in men. For this reason, thyroid-related testing can be relevant for women's health diagnostic workflows, especially when laboratories serve gynecology, endocrinology, reproductive medicine, and oncology-related follow-up needs.
On a fully automated CLIA platform, assays such as TSH, FT3, FT4, TT3, TT4, Anti-TPO, Anti-Tg, and Tg can help laboratories build a more complete endocrine and thyroid testing menu. Before publication, each assay should be checked against Wondfo's current product list, IFU, and target-market registration status.

FIA and CLIA: Complementary Roles in Women's Health Testing

While this article focuses on fully automated CLIA, immunofluorescence testing also plays an important role in women's health diagnostics. Wondfo Finecare™ FIA systems are designed for rapid quantitative testing in point-of-care and near-patient settings, including clinics, emergency departments, outpatient departments, and decentralized testing environments.
In practice, FIA and CLIA can serve complementary workflows: FIA supports rapid and flexible near-patient testing, while fully automated CLIA supports higher-throughput laboratory testing, broader automation, and centralized assay management.


 

Choosing a CLIA Platform for Women's Health Testing

When selecting a fully automated CLIA analyzer for women's health diagnostic workflows, laboratories may consider whether the system can cover more than one narrow use case. A stronger women's health menu should support reproductive hormones, thyroid and endocrine testing, gynecological tumor markers, TORCH-related assays, and supporting biomarkers. Laboratories may also consider throughput, STAT capability, reagent management, LIS connectivity, laboratory footprint, ease of operation, and future menu expansion. SmarLumi™ FC-2100 is designed to address these needs through high throughput, broad assay coverage, automated operation, and flexible testing modes.

Wondfo Solutions for Women's Health Diagnostic Workflows

Wondfo provides diagnostic solutions across immunofluorescence and chemiluminescence platforms, supporting different women's health testing scenarios from POCT to fully automated laboratory workflows. For laboratories seeking automated CLIA testing, SmarLumi™ FC-2100 offers a compact, efficient platform with women's health assay coverage across reproductive hormones, thyroid function, thyroid-related markers, gynecological tumor markers, and TORCH-related testing. For clinics and decentralized testing environments, Wondfo Finecare™ FIA systems can support rapid quantitative testing across multiple clinical areas.
Learn more: Wondfo Chemiluminescence Platform | Wondfo Immunofluorescence Platform

FAQs

What is a fully automated CLIA analyzer?

A fully automated CLIA analyzer is a laboratory system that uses chemiluminescence immunoassay technology to perform quantitative immunoassay testing with automated sample, reagent, reaction, and result management.

How does CLIA support women's health diagnostic testing?

CLIA supports women's health testing by enabling quantitative assays for reproductive hormones, pregnancy-related markers, thyroid function, thyroid autoimmunity, tumor markers, and TORCH-related testing in laboratory workflows.

Why is thyroid testing relevant to women's health diagnostics?

Thyroid function can be clinically relevant in endocrine health, reproductive health, and pregnancy-related assessment. Thyroid cancer is also diagnosed more often in women than in men, so thyroid-related testing can be part of broader women's health laboratory workflows.

What women's health assays are available on SmarLumi™ FC-2100?

SmarLumi™ FC-2100 supports women's health-related assays including β-HCG, AMH, PROG, E2, PRL, LH, FSH, TESTO, TSH, FT3, FT4, TT3, TT4, Anti-TPO, Anti-Tg, Tg, CA125, HE4, and TORCH-related markers. Product availability and intended use should be confirmed for each target market.

What is the difference between FIA and CLIA in women's health testing?

FIA is often suitable for rapid point-of-care or near-patient testing, while fully automated CLIA is more suitable for laboratories that require higher throughput, broader automation, and centralized testing workflows.

Is this article intended as medical advice?

No. This article is for professional information only. Diagnostic testing should be performed and interpreted by qualified healthcare professionals according to applicable regulations, product instructions, and clinical guidelines.

Internal Review Notes

· Confirm whether all listed assays are approved or available in the target market before publication.
· Confirm preferred spelling: use “gynecological” for SEO title and include “gynaecological” naturally if targeting UK/Commonwealth markets.
· Confirm whether the article should link directly to a SmarLumi FC-2100 product page if one is available on the current English website.